The DOI matches its Crossref record; 124 of the 132 references it cites were found in a registry or an index; 72 of the 123 sources its claims cite were checked for support.
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Open accessAbstract
Guidelines for the management of obesity and type 2 diabetes (T2DM) emphasize the importance of lifestyle changes, including a reduced-calorie diet and increased physical activity. However, for many people, these changes can be difficult to maintain over the long term. Medication options are already available to treat obesity, which can help reduce appetite and/or reduce caloric intake. Incretin-based peptides exert their effect through G-protein-coupled receptors, the receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and glucagon peptide hormones are important regulators of insulin secretion and energy metabolism. Understanding the role of intercellular signaling pathways and inflammatory processes is essential for the development of effective pharmacological agents in obesity. GLP-1 receptor agonists have been successfully used, but it is assumed that their effectiveness may be limited by desensitization and downregulation of the target receptor. A growing number of new agents acting on incretin hormones are becoming available for everyday clinical practice, including oral GLP-1 receptor agonists, the dual GLP-1/GIP receptor agonist tirzepatide, and other dual and triple GLP-1/GIP/glucagon receptor agonists, which may show further significant therapeutic potential. This narrative review summarizes the therapeutic effects of different incretin hormones and presents future prospects in the treatment of T2DM and obesity.
Overview
CoChat Summary
TL;DR
This is a narrative review of incretin-based pharmacological treatments for obesity and type 2 diabetes, focusing on GLP-1 receptor agonists and newer dual/triple agonists. It argues that semaglutide and tirzepatide are effective, and that emerging agents like cotadutide, retatrutide, orforglipron, danuglipron, and cagrilintide-based combinations may expand treatment options, though long-term safety still needs study.
Key findings
- In the STEP program, once-weekly semaglutide 2.4 mg produced about 15% weight loss in overweight/obese non-diabetic adults, and 9.6% weight loss in obese patients with T2DM (STEP-2).
- In the SURMOUNT program, tirzepatide 15 mg weekly produced about 20% body-weight reduction in overweight/obese non-diabetic adults (SURMOUNT-1 and -3), and 14.7% in overweight/obese patients with T2DM (SURMOUNT-2).
- In a 54-week study of 834 participants, cotadutide reduced HbA1c by −1.03% to −1.19% depending on dose; the highest dose lowered weight by −5.02 kg, compared with −3.33 kg for liraglutide 1.8 mg.
- Orforglipron showed dose-dependent weight loss of up to 14.7% over 36 weeks in obese, non-diabetic individuals; danuglipron produced 1.2% HbA1c reduction and 4.2 kg weight loss over 16 weeks in T2DM, and a reported 11.7% weight loss over 32 weeks in obese non-diabetic individuals, but with >50% discontinuation due to adverse events in each dose group.
Methods
- Narrative review summarizing therapeutic effects and future prospects of incretin-based therapies for obesity and T2DM.
- Literature/data sources listed as PubMed, Scopus, Web of Science, and ClinicalTrials.gov, using keywords related to obesity, T2DM, incretin hormones, GPCRs, and dual/triple agonists.
- The paper synthesizes results from clinical trials and preclinical studies; no original patient-level dataset or meta-analytic statistical model is reported.
Limitations
- The paper does not report a systematic review protocol, study selection criteria, or risk-of-bias assessment; this is evident from the text, which describes a narrative review rather than a systematic review.
- The authors explicitly note that for dual and triple GLP-1/GIP/glucagon agonists, safety needs assessment through cardiovascular outcome trials.
- The text makes evident that many conclusions rely on early-phase or ongoing studies and that several mechanisms/effects remain unclear or need further investigation (for example, GIP effects on atherosclerosis, lipid metabolism, and energy expenditure).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The incretin-based agents that are currently used in everyday medical practice or that are currently under clinical development [9].](/paper-figures/27116757221b4169b0c25b7881af600a/new-developments-in-pharmacological-treatment-of-obesity-and-type-2-figure-1.jpg)
![Figure 2 Inflammatory mediators in adipose tissue, contributing to the development of chronic inflammatory conditions [11]. GLP-1: glucagon-like peptide-1; TNF-α: tumor necrosis factor-alpha; Th1cell: T-helper 1; Th2 cell: T-helper 2 cell; IL-1β: interleukin-1β; IL-4: interleukin-4; IL-6: interleukin-6; IL-10: interleukin-10.](/paper-figures/6cb5680db1b146dbbfccd2d9ed9c9cc6/new-developments-in-pharmacological-treatment-of-obesity-and-type-2-figure-2.jpg)
![Figure 3 Activation of intracellular pathways by G-protein-coupled receptors and ligand binding, including G proteins, beta-arrestins, and other non-G-protein-regulated signaling pathways [20]. GLP-1: glucagon-like peptide-1.](/paper-figures/1f31c38591fc4dbca7f2a8847eea89a6/new-developments-in-pharmacological-treatment-of-obesity-and-type-2-figure-3.jpg)
![Figure 4 The main effects of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon [9].](/paper-figures/c2f96f073de04e70b381ae0672e202dc/new-developments-in-pharmacological-treatment-of-obesity-and-type-2-figure-4.jpg)



Verification
Claims the paper makes
52 Valid · 10 Not valid · 36 Not checked · 18 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Among obese individuals, it is possible for the phenotype of macrophages to change, indicating the dominance of proinflammatory M1-polarized macrophages over M2 macrophages involved in anti-inflammatory and reparative mechanisms.”
§ New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists > 2. The Importance of Inflammatory Processes and Oxidative Stress in Adipose Tissue
What the sources say
- Disputedcites [13] Xu, 2013, Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation, Cell Metab. sourceExperimental — accuracy not yet measured
The Discussion says the authors did not observe an obesity-driven switch from M2 to M1 macrophages. The Results likewise conclude that obesity does not induce a simple M1-polarized switch in adipose tissue macrophages. These findings are primarily from obese mice, so they do not establish the claimed M1 dominance among obese individuals. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“GIP also stimulates bone formation by inhibiting osteoclast apoptosis [52].”
§ New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists > 3. The Importance of G-Protein-Coupled Receptors in Obesity and T2DM Incretin-based peptides exert their cellular effects through G-protein-coupled receptors, which have become important therapeutic targets in the treatment of obesity and T2DM in recent years. However, the exact mechanism underlying G-protein-coupled receptors/G-protein specificity remains ambiguous and warrants further investigation [19]. G-protein-coupled receptors constitute the largest family of membrane proteins, and ligand binding can lead to activation of multiple intracellular pathways, including G proteins, beta-arrestins, and other non-G-protein-regulated signaling pathways, such as mitogen-activated protein kinase phosphorylation [20] (Figure 3). Molecules that bind directly to G-protein-coupled receptors can be either orthosteric (binding to the same pocket as the natural ligand) or allosteric (binding to a different pocket). Allosteric modulators can cooperatively interact with the natural orthosteric ligand, thereby enhancing or attenuating receptor signaling. Beta-arrestins contribute to a reduction in the response to receptor agonism through internalization of the specific G-protein-coupled receptor [21]. Presumably, the effect of native GLP-1 on the GLP-1 receptor evenly activates various signaling pathways. However, certain agonists of activated G-protein-coupled receptors can promote the activation of a subset of signaling pathways, resulting in “ligand bias” associated with unique cellular responses. Deviation from the typical effect profile of a certain receptor type is termed “biased agonism.” Certain biased agonists of the GLP-1 receptor may more strongly facilitate G-protein activation than recruitment of beta-arrestins [22]. However, it is possible that bias towards G-protein signaling may stem more from reduced activation of G-protein-coupled receptor kinases than inhibition of binding to beta-arrestins, while other studies have shown that certain β2AR ligands prefer beta-arrestin signaling over G-protein activation [23,24]. Beta-arrestin-dependent seven-transmembrane receptor signaling includes beta-arrestins, which function as multifunctional proteins regulating receptor desensitization, endocytosis, and ubiquitination while modulating G-protein signaling and promoting activation of alternative intracellular pathways. G-protein-based GLP-1 agonists appear to achieve significant weight and blood sugar-reducing effects, in part through reduced beta-arrestin recruitment, thereby avoiding receptor desensitization and downregulation [25]. β-arrestins intracellularly exert an inhibitory effect on signaling pathways mediated by G-protein-coupled receptors; concurrently, they possess the capability to regulate cellular functions independently of G proteins, such as through interaction with peroxisome proliferator-activated receptor-γ [26]. It appears that both G-protein signal activation and the beta-arrestin pathway may facilitate weight loss by inhibiting adipogenesis and inflammatory response [23,27]. Different intracellular cellular responses following binding to G-protein-coupled receptors may also explain the different efficacy of different peptide-based therapies (Figure 3). GLP-1, GIP, and glucagon receptors belong to class B G-protein-coupled receptors within the secretin receptor family. Their activation involves G protein (Gαs), leading to increased insulin secretion in beta cells via cyclic adenosine monophosphate (cAMP) production, but they also activate the beta-arrestin pathway, which impedes G-protein signaling. Each receptor undergoes agonist-induced endocytosis to varying degrees, thus fine-tuning spatial and temporal modulation of intracellular signaling and hormonal response [28]. During biased agonism, the balance between receptor recruitment, activation of intracellular signaling, and subsequent receptor trafficking may be ligand specific. There are numerous examples of biased agonism at the GLP-1 receptor, including both natural and pharmacological orthosteric agonists. Biased GLP-1 receptor agonists derived from exendin-4 result in prolonged insulin secretion by reducing GLP-1 receptor desensitization and endocytosis, as well as mitigating GLP-1 receptor downregulation [29]. The dual GLP-1/GIP receptor agonist tirzepatide exhibits unbalanced dual agonism at GLP-1 and GIP receptors, but with significantly lower affinity for the GLP-1 receptor and much milder cAMP activation [30]. GLP-1, GIP, and glucagon receptors are present on pancreatic beta cells, and their physiological or pharmacological activation leads to significant metabolic effects [9] (Figure 4). Activation of all three receptors enhances glucose-stimulated insulin secretion, but they differ in their effects on fasting and postprandial blood glucose levels, gluconeogenesis, and lipogenesis, while their common effects include increased energy expenditure and enhanced satiety for weight loss [31]. GLP-1 receptor agonists moderate fasting and postprandial blood glucose levels and, beyond their weight-reducing effects, have demonstrated anti-atherogenic protection in terms of cardiovascular diseases [32,33]. In the case of GIP analogs, beyond effective blood sugar reduction, they have also shown effects on food intake and weight loss, especially when combined with GLP-1 receptor agonists. However, the effects of GIP on fatty acid metabolism, atherosclerosis, adipose tissue metabolic activity, and energy expenditure remain unclear [33]. Despite glucagon’s blood sugar-increasing effect, glucagon receptor activation moderates food intake, enhances fatty acid breakdown, and increases energy expenditure, supporting the rational use of glucagon in combination with other incretin hormones in the treatment of obesity and T2DM [34]. > 3.2. The Main Effects of Glucose-Dependent Insulinotropic Polypeptide Glucose-dependent insulinotropic polypeptide (GIP) is produced from K cells in the mucosa of the small intestine and exerts its effects through a receptor coupled to a G protein. The glucose-dependent insulin-releasing effect of GIP, like GLP-1, is impaired in T2DM, but combining them may further improve beta-cell function and insulin secretion [50] (Figure 4). Similar to GLP-1, GIP also inhibits beta-cell apoptosis in the pancreas, thereby improving its survival during T2DM progression [51]. GIP also stimulates bone formation by inhibiting osteoclast apoptosis [52]. The precise effects of GIP on lipid metabolism are currently unclear; some studies suggest it may increase lipid uptake in adipose tissue and decrease lipolysis [53,54], while others suggest GIP may have lipolytic activity, as adipose tissue from transgenic mice overexpressing GIP has been found to be resistant to high-fat feeding [55,56]. It is hypothesized that by enhancing lipid-buffering capacity and insulin sensitivity in white adipose tissue postprandially, GIP may prevent ectopic fat deposition between tissues and muscles [57]. Activation of GIP receptors improved blood glucose levels in obese mouse models without altering body weight or fat tissue quantity [58], and activation of GIP receptors in the hypothalamus reduced food intake as well [59]. Whole-genome association studies have shown associations between different activity levels of human GIP receptor variants and the degree of obesity [60]. The anti-inflammatory effect of GIP on atherosclerosis is not clear from preclinical studies; therefore, the role of GIP in the atherosclerosis process seems to be controversial at the moment. In cell cultures, the administration of GIP may exert both anti-atherogenic effects (increased nitric oxide and adiponectin concentration, decreased endothelin-1 levels, reduced oxidative stress, decreased migration and proliferation of fibroblast cells) and pro-atherogenic effects (decreased adiponectin levels, increased endothelin-1 and osteopontin levels) [61]. In another study, high-dose administration of GIP reduced macrophage translocation into the vessel wall, thereby reducing foam cell formation, decreasing matrix metallopeptidase-9 activity and interleukin-6 secretion, and ultimately reducing the size of atherosclerotic plaques [62]. In summary, besides effectively reducing blood sugar levels, GIP analog treatment has also been shown to affect food intake and weight loss, especially when combined with GLP-1 receptor agonists. However, the detailed effects of GIP on lipid metabolism, atherosclerosis, metabolic activity of adipose tissue, and energy expenditure are still unclear.
What the sources say
- Disputedcites [52] Tsukiyama, 2006, Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion, Mol. Endocrinol. sourceExperimental — accuracy not yet measured
The ‘Antiapoptotic Effect of GIP on Osteoblasts’ section reports that GIP prevented apoptosis of osteoblasts, not osteoclasts. The ‘No Direct Effect of GIP on Osteoclasts’ section says GIP did not directly inhibit osteoclast function. The claim names the wrong cell type for the reported antiapoptotic effect. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Previous large randomized clinical trials have demonstrated that a 3 mg dose of liraglutide can result in an average weight loss of 5.6 kg over nearly one year in overweight or obese individuals without diabetes [71].”
§ New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists > 4. Peptide-Based Therapies in the Treatment of Obesity
What the sources say
- Disputedcites [71] Astrup, 2015, A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The Results (p. 1) report that the liraglutide group lost a mean of 8.4 kg at 56 weeks. The cited 5.6 kg is the difference in mean weight loss between the liraglutide and placebo groups, not the average loss among those receiving liraglutide. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“While inhibition of the appetite-stimulating (orexigenic) hormone ghrelin may seem an attractive therapeutic target, studies targeting ghrelin receptor inhibition have not reported sufficient efficacy to encourage further clinical development [124].”
§ New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists > 6. Studies with Other Weight-Loss Medications
What the sources say
- Disputedcites [124] Altabas, 2015, Anti-ghrelin antibodies in appetite suppression: Recent advances in obesity pharmacotherapy, Immunotargets Ther. sourceExperimental — accuracy not yet measured
In “Vaccination as a form of obesity prophylaxis and/or treatment” (page unavailable), the paper reports that ghrelin receptor antagonists suppressed appetite and produced weight loss in rodents, calling ghrelin blocking a potential treatment target. Its disappointing human trial concerned an anti-ghrelin vaccine, not receptor inhibition; the paper does not conclude that receptor-antagonist studies lacked sufficient efficacy for further clinical development. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Numerous inflammatory mediators are produced in adipose tissue, significantly contributing to the development of chronic inflammatory conditions [11]”
§ New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists > 2. The Importance of Inflammatory Processes and Oxidative Stress in Adipose Tissue
What the sources say
- Supportedcites [11] Riddy, 2018, G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus, Pharmacol. Rev. source
The ‘Obesity-Induced Type 2 Diabetes Mellitus’ section describes the release of multiple inflammatory mediators in adipose tissue and links immune-cell infiltration there to chronic low-grade inflammation. This supports the claim in the paper’s obesity-related metabolic context. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
50 more claims · 24 with their cited sources checked
Create a free account to see all 116 claims and to verify the 8 references still open.
- It may state two separate claims as one. 57
- Probably not a substantial claim. 8
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“In the SURMOUNT-1 and -3 studies, tirzepatide administered at a high dose of 15 mg subcutaneously once weekly resulted in approximately a 20% reduction in body weight in overweight and obese, non-diabetic adults, even after up to 2 years of treatment [84,85].”
BackgroundSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“Previous large randomized clinical trials have demonstrated that a 3 mg dose of liraglutide can result in an average weight loss of 5.6 kg over nearly one year in overweight or obese individuals without diabetes [71].”
BackgroundInfluentialPhelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544 · cited 1×
“Obesity is responsible for approximately 43% of all cases of type 2 diabetes, with rates as high as 80–85% in some populations [1].”
BackgroundMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“…e ff ect of incretin hormones on left ventricular diastolic dysfunction, common in T2DM [39,40]. to its and inotropic effects on cardiac muscle cells, GLP-1 slightly increases which is counteracted by the favorable effect of incretin hormones on left diastolic dysfunction, common in T2DM [39,40].”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Research works printed but not linked: 1
- Pfizer Inc. (2024, March 27). Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity. Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r.
Cited by
Features, functions, and associated diseases of visceral and ectopic fat: a comprehensive review
Luo, J., Wang, Y., Mao, J., Yuan, Y., Luo, P. F., Wang, G., & Zhou, S. (2025) · Obesity · doi:10.1002/oby.24239 · Cited by 53
Sallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 20
Chen, K.-Y., Chan, H.-C., & Chan, C.-M. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100245 · Cited by 25
Anastasiou, I. A., Kounatidis, D. C., Rebelos, E., Vallianou, N. G., Tentolouris, A., Tentolouris, N., Dalamaga, Μ., & Karampela, Ι. (2025) · Medicina · doi:10.3390/medicina61101724 · Cited by 14
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“Some new innovative synthetic drugs, either already in use or yet under research, have shown good results in obesity and T2DM and might become useful for the treatment of MASLD, MASH, and subsequent hepatic cirrhosis [59,60].”
Metadata
- Authors
- Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M.
- Affiliations
- University of Debrecen (HU)
- Corresponding author
- Sztanek, Ferenc
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2024-06-13
- Volume
- 12
- Issue
- 6
- Pages
- 1320
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC11201978
- OpenAlex
- W4399623216
- Cited by
- 47
- References
- 132
- Citations by year
- 2026: 21 · 2025: 23 · 2024: 3
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Research, Development and Innovation Office (K142273, TKP2021-EGA-18, 11003)
- Ministry of Innovation and Technology of Hungary from the National Research (K142273, TKP2021-EGA-18, 11003)
- Eötvös Loránd Research Network (K142273, TKP2021-EGA-18, 11003)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- obesity, type 2 diabetes, GLP-1 receptor agonists, incretin-based therapy, glucose-dependent insulinotropic polypeptide, tirzepatide, GIP/GLP-1 receptor agonist, glucagon receptor agonist, receptor desensitization, G protein-coupled receptors, appetite regulation, energy metabolism, inflammation, pharmacotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists. https://app.cochat.ai/papers/10.3390/biomedicines12061320
- The paper
- Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024). New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists. Biomedicines. https://doi.org/10.3390/biomedicines12061320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.